Please login to the form below

Not currently logged in
Email:
Password:

Takeda regains Prostap from Wyeth

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland.

Under the agreement, marketing authorisation for Prostap, a prostate cancer therapy, would return to the drug's developer, Takeda. The Japanese-owned company signed over the marketing authorisation for the product in the UK and Republic of Ireland to Wyeth in 1990.

Marketing for the entire Prostap product range in the UK and Republic of Ireland will revert to Takeda from July 1, 2009.

"The addition of Prostap will enrich our product portfolio, which currently consists of Amias, Actos and Competact, and is a logical development of our plan to develop a substantial franchise in the oncology market", commented Trevor Smith, Takeda UK's managing director.

Prostap is used for the treatment of prostate cancer, endometrisis and uterine fibroids. It is marketed in around 80 countries and is considered a gold standard therapy for prostate cancer.

26th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics